Unknown

Dataset Information

0

CRKL Mediates p110?-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.

ABSTRACT: The p110? isoform of PI3K is preferentially activated in many tumors deficient in the phosphatase and tensin homolog (PTEN). However, the mechanism(s) linking PTEN loss to p110? activation remain(s) mysterious. Here, we identify CRKL as a member of the class of PI3K?-interacting proteins. Silencing CRKL expression in PTEN-null human cancer cells leads to a decrease in p110?-dependent PI3K signaling and cell proliferation. In contrast, CRKL depletion does not impair p110?-mediated signaling. Further study showed that CRKL binds to tyrosine-phosphorylated p130Cas in PTEN-null cancer cells. Since Src family kinases are known both to be regulated by PTEN and to phosphorylate and activate p130Cas, we tested and found that Src inhibition cooperated with p110? inhibition to suppress the growth of PTEN-null cells. These data suggest both a potential mechanism linking PTEN loss to p110? activation and the possible benefit of dual inhibition of Src and PI3K for PTEN-null tumors.

SUBMITTER: Zhang J 

PROVIDER: S-EPMC5704918 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.

Zhang Jing J   Gao Xueliang X   Schmit Fabienne F   Adelmant Guillaume G   Eck Michael J MJ   Marto Jarrod A JA   Zhao Jean J JJ   Roberts Thomas M TM  

Cell reports 20170701 3

The p110β isoform of PI3K is preferentially activated in many tumors deficient in the phosphatase and tensin homolog (PTEN). However, the mechanism(s) linking PTEN loss to p110β activation remain(s) mysterious. Here, we identify CRKL as a member of the class of PI3Kβ-interacting proteins. Silencing CRKL expression in PTEN-null human cancer cells leads to a decrease in p110β-dependent PI3K signaling and cell proliferation. In contrast, CRKL depletion does not impair p110α-mediated signaling. Furt  ...[more]

Similar Datasets

Unknown PI3K-p110? mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
| S-EPMC4846581 | biostudies-literature
Unknown SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer.
| S-EPMC4255362 | biostudies-literature
Unknown Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
| S-EPMC3142785 | biostudies-literature
Transcriptomics PTEN regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression
2023-11-01 | GSE242387 | GEO
Unknown MiR-202-5p/<i>PTEN</i> mediates doxorubicin-resistance of breast cancer cells via PI3K/Akt signaling pathway.
| S-EPMC6606016 | biostudies-literature
Unknown PTEN contributes to profound PI3K/Akt signaling pathway deregulation in dystrophin-deficient dog muscle.
| S-EPMC2671376 | biostudies-other
Unknown Enhanced PI3K p110? signaling confers acquired lapatinib resistance that can be effectively reversed by a p110?-selective PI3K inhibitor.
| S-EPMC3902650 | biostudies-literature
Unknown Combined Inhibition of Both p110? and p110? Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer.
| S-EPMC5449270 | biostudies-literature
Unknown Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities.
| S-EPMC3923315 | biostudies-literature
Unknown Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells.
| S-EPMC7801611 | biostudies-literature